ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC)

jwray01 (99.64) Submitted: 8/3/2012 3:44:14 AM : Start Price: $2.95 IMUC Score: +33.70

1. microcap stock spam / endlessly pumped on Seeking Alpha2. went public in a reverse-merger to avoid SEC oversight3. Book value of 6M, while burning cash at 3M per quarter.4. reckless dilution and accounting shenanigans in the latest 10-Q filing which I read. They give stock options to outside "investor relations" firms to pump their stock.5. took them 6 years to get their lead drug candidate through phase 1 trials, which only screen for safety, not efficacy.6. Glioblastoma Multiforme affects only 2-3 in 100,000 people, so even if they win the lottery and their drug is successful, the upside is small.